$223,158.02 ownership Payment -- Amgen Inc to Dr. Rebecca Adams

Payment Details

AI-Powered Analysis of This Payment

The following analysis was generated by artificial intelligence to help patients understand the context, significance, and implications of this pharmaceutical payment. This analysis is not medical or legal advice.

Amgen Inc made a $223.2K ownership payment to Rebecca Adams, a Oncology specialist in Albany, NY. The payment was associated with Farxiga. Significant ownership interest reported by Dr. Adams in Amgen Inc. The total value of the ownership interest is substantial at $223,158.02. This ownership is linked to Farxiga, a drug relevant to Oncology.

Patient Guidance: What This Payment Means for You

This record indicates a physician has an ownership interest in a pharmaceutical company. It's important to understand how such financial relationships might influence treatment decisions. Always discuss your treatment options with your healthcare provider and ask about alternatives.

Payment Context: Is This Amount Normal?

Ownership interests in pharmaceutical companies are less common than payments for consulting or speaking, and the substantial amount here warrants attention within the Oncology specialty.

Regulatory Context: Sunshine Act Requirements

Physicians are required to disclose ownership interests in pharmaceutical companies under the Sunshine Act to ensure transparency in healthcare.

Related Topics

This payment is related to the following healthcare transparency topics:

• ownership-interest
• pharma-investment
• oncology
• amgen-inc
• farxiga
• physician-disclosure

Understanding ownership Payments

Ownership and investment interest payments represent dividends, returns, or other financial benefits from physician ownership stakes in pharmaceutical or medical device companies. These relationships represent the most direct form of financial interest and are subject to the strictest reporting requirements under the Sunshine Act.

Frequently Asked Questions About This Payment

What was this $223.2K payment for?

This was a ownership payment of $223.2K from Amgen Inc to Rebecca Adams, categorized as "Ownership or Investment Interest". It was associated with Farxiga. The payment was reported under the Sunshine Act (CMS Open Payments).

Does Rebecca Adams accept pharmaceutical money?

Yes, Rebecca Adams received this $223.2K payment from Amgen Inc. Under the Sunshine Act, pharmaceutical companies must report all payments to physicians exceeding $10. You can view Rebecca Adams's full payment history on the CMS Open Payments database or on this site.

Is it legal for doctors to accept pharma payments?

Yes, it is legal for physicians to receive payments from pharmaceutical companies. The Physician Payments Sunshine Act (2010) requires transparency by mandating that companies report all payments exceeding $10 to CMS. These payments include consulting fees, meals, travel, speaking fees, and research grants. The law does not prohibit payments but ensures public disclosure.

Should I be concerned about this ownership payment?

A ownership payment of $223.2K should be evaluated in context. Payment does not imply wrongdoing, but patients have the right to ask their doctor about pharmaceutical relationships.

How do I talk to my doctor about pharma relationships?

You can ask your doctor directly: "Do you receive payments from pharmaceutical companies?" and "Does this affect which medications you prescribe?" Most doctors will answer honestly. You can also verify payment data yourself through CMS Open Payments (openpaymentsdata.cms.gov). Consider asking about generic alternatives and whether the prescribed medication is the best option regardless of manufacturer relationships.

What types of pharma payments are most concerning?

Ownership interests and large consulting/speaking fees are generally considered more significant than meals or small educational grants. Research payments typically fund clinical studies and are common in academic medicine. The total volume and concentration of payments from a single company may be more telling than any individual payment. Patterns matter more than individual transactions.

Does pharma money affect what my doctor prescribes?

Research shows that even small payments can influence prescribing behavior. Studies published in JAMA Internal Medicine found that physicians who received meals costing as little as $20 were more likely to prescribe the promoted brand-name drug. However, many physician-industry interactions are legitimate professional activities. The key is transparency and awareness.

How does this compare to other doctors in Oncology?

To compare this payment against Oncology averages, check the full specialty breakdown on CMS Open Payments. Payment amounts vary widely by specialty and type. Oncology physicians may receive payments for consulting, speaking, or research that are standard for the field. Individual payments should be evaluated in the context of the doctor's full payment history.

What does this payment reveal about Rebecca Adams's relationship with Amgen Inc?

The payment type is 'ownership', indicating a financial stake rather than a direct payment for services. This $223.2K ownership payment is part of the transparency data reported under the Sunshine Act.

Is this payment amount typical for Oncology?

The payment nature is explicitly 'Ownership or Investment Interest'.

What should patients do after learning about this payment?

This record indicates a physician has an ownership interest in a pharmaceutical company. It's important to understand how such financial relationships might influence treatment decisions.

What else should I know about this ownership payment?

The specialty is Oncology, and the drug mentioned is Farxiga.

Related Reports

• View Dr. Rebecca Adams's full payment report
• Amgen Inc full spending report
• Browse all Oncology payments
• Browse all payments in New York
• Search for other payments